TICKERNERD
Menu
AORTAORTHealthcare · Medical Devices

AORT Stock Forecast: Artivion, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$28
+0.36% on the day

The 8 Wall Street analysts covering Artivion, Inc. hold a median 12-month price target of $42 — +49.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 45 of 100 as at 21 Aug 2026 — in the lower half.

Market cap
$1.4B
Ticker Nerd rank
45 / 100
Median analyst target
$42
Analysts covering
8
Total return, dividends reinvested
1W
−3.6%
1M
+12.6%
YTD
−38.4%
1Y
−34.9%
From 52W high
−41.0%
From 52W low
+39.7%
$20
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AORT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Artivion, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
45 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
86
Volatility
75
Quality
70
Value
59
Momentum
45
Size
41
Accruals
40
Revisions
39
Issuance
14

Growth (86): Sales and profits are climbing, and climbing faster than before.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AORT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AORT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40$45$50Oct 25Jan 26Apr 26Jul 26AORTHigh $48Median $42Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $38Median $42High $48

The green dot is the last close — the median target sits +49.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Aug 2026Canaccord GenuityMaintainsBuy$39 → $40
20 July 2026NeedhamReiteratesBuy—
20 July 2026NeedhamReiteratesBuy$44
16 June 2026Canaccord GenuityMaintainsBuy$36
16 June 2026Canaccord GenuityMaintainsBuy—
8 May 2026CitizensMaintainsMarket Outperform—
8 May 2026NeedhamMaintainsBuy—
10 Apr 2026Ladenburg ThalmannUpgradeBuy—
7 Apr 2026NeedhamReiteratesBuy—
13 Feb 2026Canaccord GenuityMaintainsBuy—
2 Feb 2026NeedhamReiteratesBuy—
7 Nov 2025Canaccord GenuityMaintainsBuy—
7 Nov 2025CitizensMaintainsMarket Outperform—
7 Nov 2025NeedhamMaintainsBuy—
10 Oct 2025JMP SecuritiesMaintainsMarket Outperform—
29 Sept 2025Canaccord GenuityMaintainsBuy—
29 Sept 2025StifelMaintainsBuy—
22 Aug 2025NeedhamMaintainsBuy—
13 Aug 2025Ladenburg ThalmannDowngradeNeutral—
8 Aug 2025Canaccord GenuityMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AORT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

AORT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−14.5%
Analysts raising
0
Analysts cutting
1
Fundamentals

Artivion, Inc. (AORT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
106.2×

Cheaper than 7% of US stocks

Price / sales
2.9×

Cheaper than 43% of US stocks

Price / book
3.1×

Cheaper than 34% of US stocks

EV / EBITDA
26.7×

Cheaper than 10% of US stocks

Growth & margins
Revenue growth (YoY)
11.3%

Higher than 56% of US stocks

Earnings growth (YoY)
11.3%

Higher than 50% of US stocks

Gross margin
64.0%

Higher than 78% of US stocks

Operating margin
9.0%

Higher than 62% of US stocks

Net margin
−0.7%

Higher than 29% of US stocks

Returns & dividend
Return on equity
−0.7%

Higher than 43% of US stocks

Return on assets
2.6%

Higher than 62% of US stocks

Dividend yield
0.4%

Higher than 8% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AORT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
AORTArtivion, Inc.$1.4B
45
ATECAlphatec Holdings, Inc.$1.4B
76
IARTIntegra LifeSciences Holdings Corp.$1.3B
90
ENOVEnovis Corp.$1.5B
86
PRCTPROCEPT BioRobotics Corp.$1.2B
38
TNDMTandem Diabetes Care, Inc.$1.6B
64
BVSBioventus, Inc.$1.2B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Artivion, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AORT news & analysis

Artivion Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

Artivion reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, driven by growth in stent grafts and On-X heart valves that offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while the adjusted EBITDA margin fell roughly 90 basis points to 21% amid higher R&D spending and costs related to the Endospan acquisition.

Why it matters — The results detail how segment growth is offsetting BioGlue declines and how higher spending related to R&D and the Endospan acquisition is affecting Artivion's margins.

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of Artivion, Inc.'s Q2 2026 earnings call, offering a detailed account of the company's quarterly results discussion. The excerpt provided contains only the transcript's headline identifying the call and its source.

Why it matters — A transcript of Artivion's Q2 2026 earnings call gives investors and analysts a complete record of management's commentary on the company's quarterly performance.

Artivion (AORT) Q2 Earnings Meet Estimates

Zacks Investment Research · 6 Aug 2026neutral

Artivion reported Q2 earnings of $0.13 per share, matching the Zacks Consensus Estimate. This compares to earnings of $0.24 per share in the same quarter a year ago.

Why it matters — AORT watchers would note whether the company's earnings continue to meet consensus expectations despite the year-over-year decline.

Artivion Reports Second Quarter 2026 Financial Results

PRNewsWire · 6 Aug 2026positive

Artivion reported second quarter 2026 revenue of $125.8 million, up 11% from $113.0 million a year earlier, with a GAAP net loss of $(13.5) million and non-GAAP net income of $6.3 million. The company also announced FDA PMA approval of its AMDS Hybrid Prosthesis and completed its acquisition of Endospan Ltd.

Why it matters — The quarter shows revenue growth and higher adjusted EBITDA, while FDA approval of the AMDS Hybrid Prosthesis and the completed Endospan acquisition expand Artivion's product portfolio and pipeline.

Artivion to Participate in Upcoming Investor Conferences

PRNewsWire · 28 July 2026neutral

Artivion announced that its management team will present at the Canaccord Genuity 46th Annual Growth Conference on August 12, 2026.

Why it matters — Investor conferences give Artivion an opportunity to present its business to the investment community, which may increase visibility among potential investors.

FAQ

Frequently asked questions about AORT stock

What is the AORT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Artivion, Inc. have a median 12-month price target of $42, with estimates ranging from $38 to $48. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AORT stock a buy right now?

Of the 8 analysts covering Artivion, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Artivion, Inc. 45 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AORT?

As at 21 Aug 2026, Artivion, Inc. ranks 45 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (86 of 100).

Will AORT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +49.6% from the last close, and Ticker Nerd's factor model ranks Artivion, Inc. 45 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AORT stock forecast for 2030?

No analyst covering Artivion, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AORT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $48 over the next 12 months.

How has AORT stock performed over the past year?

Artivion, Inc. returned -34.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Artivion, Inc. do?

Artivion Inc. is a medical device company focused on providing innovative technology solutions aimed at improving patient outcomes.

What is the latest news on AORT?

The most recent item we track (MarketBeat, 7 Aug 2026): "Artivion Q2 Earnings Call Highlights". Artivion reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, driven by growth in stent grafts and On-X heart valves that offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while the adjusted EBITDA margin fell roughly 90 basis points to 21% amid higher R&D spending and costs related to the Endospan acquisition.

Company

About Artivion, Inc.

Artivion Inc. is a medical device company focused on providing innovative technology solutions aimed at improving patient outcomes. Its primary function is to develop, manufacture, and sell devices associated with cardiac and vascular surgery, with a particular emphasis on cryopreservation and heart valve structures. The company's product portfolio serves critical areas such as aortic repair, heart valve therapy, and advanced cryogenic preservation techniques, underpinning its vital presence in the cardiovascular treatment sector. Its products are essential in supporting cardiac surgeons and healthcare professionals in utilizing life-saving technologies during complex medical procedures. Artivion Inc. serves a global market, impacting numerous aspects of healthcare by enabling the treatment of complex heart conditions and elevating surgical efficiency and efficacy. Headquartered in the United States, the company continues its commitment to innovation and quality in medical technology, playing a crucial role in advancing health outcomes and directly contributing to the fields of cardiovascular surgery and transplant medicine.

CEO Mr. James Patrick Mackin · 1,600 employees · United States · https://artivion.com